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Abstract
OBJECTIVE: To observe the effect of Sancaijiang-
tang powders on plasma nitric oxide and endothe-
lin-1 levels. We sought to identify the common
pathological link and mechanism of action for Tradi-
tional Chinese medicine in type 2 diabetes mellitus
and vascular dementia, and to explicate the materi-
al basis for treating the different diseases with the
same method in Traditional Chinese Medicine.
METHODS: In total, 168 patients with type 2 diabe-
tes mellitus and vascular dementia were enrolled in
the study, and randomly divided into two groups
by simple randomization. Patients in the treatment
group received oral Sancaijiangtang powders with
pioglitazone hydrochloride three times daily, while
patients in the control group received pioglitazone
hydrochloride alone. The treatment course was for
12 weeks. Mini-mental state examinations (Chinese
version) and Montreal Cognitive Assessments (Bei-
jing version) were performed, and fasting plasma
glucose, fasting insulin, hemoglobin A1c, homeo-
stasis model assessment of insulin resistance, plas-
ma nitric oxide and endothelin-1 levels were mea-
sured before and after the treatment.
RESULTS: The post-treatment levels for all measure-
ments in both groups were better than pre-treat-
ment levels (P < 0.05). The post-treatment levels for
all measurements in the treatment group were bet-
ter than the levels measured in the control group
(P < 0.05).
CONCLUSION: Type 2 diabetes mellitus and vascu-
lar dementia have common pathological mecha-
nisms for insulin resistance and endothelium dys-
function. Sancaijiangtang powders could improve
the release of nitric oxide and inhibit the secretion
of endothelin-1. Therefore, the material basis exists
for treating the different diseases with the same
method in Traditional Chinese Medicine.
© 2015 JTCM. All rights reserved.
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INTRODUCTION
The basic principle of treating different diseases with
the same method in Traditional Chinese Medicine
(TCM) was suggested by Huang Di Nei Jing.1 This
meant that if different diseases had the same pathogene-
sis, the treatment with TCM could be applied using
the same method. The same pathophysiological mecha-
nism is not the only common biological basis for the
development process of different diseases, but also the
material basis of the clinical efficacy of TCM.2
Diabetes mellitus (DM) is a metabolic disease charac-
terized by hyperglycemia as a result of insulin resis-
tance (IR) and beta-cell failure. Diabetes is one of the
main contributors to ill health and premature mortali-
ty worldwide, and the population with diabetes is ex-
pected to increase from 171 million to 366 million.3
Ischemic vascular dementia (VaD) is a clinical syn-
drome of acquired intellectual impairment with isch-
emic cerebral injury, and resulting from occlusion of ce-
rebral blood vessels and loss of cerebral tissue caused by
cerebrovascular disease.4 Both diseases are closely relat-
ed to IR, hyperinsulinemia, and endothelial dysfunc-
tion (ED).5,6 Large-scale epidemiological studies have re-
ported that the incidence of dementia in diabetic pa-
tients is two- to threefold higher than in non-diabetic
patients.7 IR is closely associated with ED. The exis-
tence of either VaD or IR affects the other, and increas-
es onset. Some studies have shown that ED is impor-
tant in the pathogenesis of vascular damage in DM, as
is indicated by plasma nitric oxide (NO) and endothe-
lin-1 (ET-1) levels. There are advantages in preventing
and treating IR and ED with TCM, which promotes
clinical, scientific research and the development of new
drugs.
Traditional principles for using Sancaijiangtang pow-
ders to clear heat and moisten dryness suggest a balanc-
ing of Yin and Yang. Many laboratory and clinical stud-
ies have confirmed the existence of effective compo-
nents or compound preparations of TCM, and those
which were superior in improving IR, and protecting
vascular endothelial cells and islet beta-cells.8 This
study aimed to observe the effect of Sancaijiangtang
powders on NO and ET-1 levels. In addition to this,
we aimed to discuss the potential for treating both type
2 diabetes mellitus and VaD with TCM.
MATERIALS ANDMETHODS
Design
A single-blind randomized controlled trial (RCT) was
conducted, and with patients blind to the drug condi-
tions. Trial evaluators were formally trained physicians.
Randomization was undertaken by a computer using
random number tables for each condition. Allocation
of treatment conditions was known to the physicians
and nurses who physically administered the drugs to
the patients. Sample size was calculated by an inspec-
tion level where α=0.05, the power of a test was 0.80,δ=10%, and the losing ratio was 10%. The duration of
the study was 13 weeks (1 week to allow for patient se-
lection, and 12 weeks for the duration of treatment).
Patients
Outpatients and inpatients with type 2 DM and VaD
were selected at the Department of Endocrinology and
Department of Neurology at the Teaching Hospital of
Chengdu University of Traditional Chinese Medicine,
from July 2013 to July 2014. All patients conformed
to the type 2 DM diagnostic criteria stipulated by the
WHO (1999),9 the Diagnostic and Statistical Manual
of Mental Disorders, and the 4th edition of the criteria
for dementia,10 and the criteria for probable VaD from
the National Institute of Neurological Disorders and
the Stroke Association Internationale pour la Recher-
che et l'Enseignement en Neurosciences.11 The study
comprised of 80 women and 88 men, with a mean age
of (59 ± 11) years, and a mean disease course of (15 ±
2) years. This research study was approved by the Insti-
tutional Review Board of the Teaching Hospital of
Chengdu University of Traditional Chinese Medicine,
with all patients and/or their guardians giving signed
informed consent.
Inclusion criteria
The inclusion criteria were as follows: (a) an age range
of 45-75 years; (b) patients with normal liver and kid-
ney function; (c) patients receiving oral antidiabetic
drugs and/or insulin injections, with a stable therapeu-
tic method and dosage for one month; (d) patients
with mild VaD assessed by the clinical dementia rating
scale, and a disease course ≥ 3 months; (e) patients
with an Hachinski ischemia scale score ≥ 5; (f ) patients
with enough visual and aural discrimination for scale
testing; and (g) cerebrovascular disease shown by com-
puted tomography and/ormagnetic resonance imaging.
Exclusion criteria
The exclusion criteria were as follows: (a) patients with
type 1 DM or any specific types of diabetes other than
type 2 DM; (b) patients with a history of severe hypo-
glycemia; (c) patients with acute or chronic complica-
tions of DM; (d) patients with severe primary diseases
of the liver and kidney (alanine aminotransferase or as-
partate amino transferase ≥ 3 times, total bilirubin in
serum > 1.5 times, serum creatinine, > 115 μmol/L);
(e) women preparing for pregnancy, or pregnant or lac-
tating women; (f ) patients participating in other clini-
cal studies that could have influenced the present
study; (g) patients with schizophrenia or severe depres-
sion (a Hamilton depression scale score ≥12), or men-
tal illness; (h) patients with history of neurosurgery
that may continue to cause cognitive impairment, oth-
er types of dementia or neurological diseases; (i) pa-
tients with aphasia, disturbance of consciousness, or
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not taking care of themselves in life; and (j) patients us-
ing drugs to treat VaD within 30 days before the start
of this study.
Treatment
Patients in the control group were treated with piogli-
tazone hydrochloride (Kerui Pharmaceutical, Compa-
ny, Chongqing, China) at 30 mg/d. Patients in the
treatment group were treated with Chinese medicinal
Sancaijiangtang powders and with pioglitazone hydro-
chloride. The herbs were purchased from the Pharmacy
Department of the Teaching Hospital of Chengdu,
University of Traditional Chinese Medicine (Sichuan,
China). The recipe consisted of Renshen (Panax Gin-
seng), Tiandong (Asparagus Racemosus), Shengdi (Radix
Rehmanniae), Wumei (dark plum fruit), Rougui (Cor-
tex Cinnamomi), Huanglian (Rhizoma Coptidis). The
Chinese medicinal powders (prepared by the Teaching
Hospital of Chengdu University of Traditional Chinese
Medicine, with 9 g/bag) were taken orally three times
daily, 9 g/bag a dose. Both groups were given basic
treatment which included a diet, health education and
sporting exercise. Four treatment courses of continuous
therapy were provided over 12 weeks.
All of the patients were individually guided by endocri-
nologists to plan their diet. The daily total requirement
of heat was 30 kcal/kg for an ideal body weight, [actual
height (cm) -105]. The proportions of carbohydrates,
fats, and proteins were stipulated at 50% , 35% and
50% respectively, and the proportion of the total quan-
tity of heat was 1:2:2 daily. Mealtimes and foods were
relatively consistent. Health education about DM was
instructed by the endocrinologists and nurses every
Wednesday and Friday afternoon. Exercise programs
were done under the supervision of the endocrinolo-
gists and nurses to urge patients to do active aerobic ex-
ercises (heart rate = 170-age).
Elbow venous blood was collected during the next
morning (i.e. patients had abrosia for more than 12 h).
The detection index and methods were as follows. Fast-
ing plasma glucose (FPG) and fasting insulin (FIns)
were tested using a Hitachi 7600 auto biochemistry in-
strument (Kabushiki Kaisha Hitachi high-tech compa-
nies, Japan). HbA1c was tested by High-performance
liquid chromatography (HPLC). IR was calculated by
Homeostasis Model Assessment (HOMA),12 where
HOMA-IR = FPG × Fins/22.5. ET-1 was tested using
an enzyme linked immunosorbent assay (ELISA). NO
was tested using nitrate reductase. Experimental data
were tested in endocrinology laboratory of teaching
hospital of Chengdu University of TCM.
All of the patients were evaluated by neuropsychologi-
cal testing which included a Mini-Mental State Exami-
nation (MMSE) (Chinese version) and Montreal Cog-
nitive Assessment (MoCA) (Beijing Chinese version)
using standardized language in quiet conditions.
MMSE and MoCA were performed within 10 min-
utes. The tests were repeated by two different physi-
cians and given analytic judgment, if there were prob-
lems, the tests were decided by a third party. with a
time interval of greater than 1 h between tests. A Clock
Drawing Test (CDT) was performed at three time
points. The above scales were tested by neurologists
who were trained professionally.
Statistical analysis
All data were analyzed using SPSS version 18.0 (Boyi
Consultant Information Technology Company, Bei-
jing, China). Quantitative data fitting a normal distri-
bution was expressed as mean ± standard deviation,
while ill-fitting data were analyzed using non-paramet-
ric tests. The χ2 test was used for enumerated data. An
independent sample t-test was used for quantitative da-
ta fitting a normal distribution when there was equal
variance between two groups. A paired sample t-test
was used to compare the data from the two groups be-
fore and after treatment. Quantitative data not fitting a
normal distribution or data with an unequal variance
was analyzed using a Wilcoxon rank sum test. P < 0.05
was considered as a statistically significant difference.
RESULTS
Enrollment and completion
In total, 241 cases of type 2 DM and VaD were prelim-
inarily selected. Reasons for withdrawal during enroll-
ment were as follows. There were 32 cases that did not
meet the inclusion criteria. Eleven patients declined to
participate. Fourteen cases were withdrawn for other
reasons. Thereafter, 184 cases were randomly divided
into two groups by simple randomization using ran-
dom number tables, with 93 cases assigned to the treat-
ment group and 91 cases to the control group. Seven
patients withdrew from the treatment group and nine
patients withdrew from the control group. Reasons for
withdrawal during the test were as follows. Four cases
were unable to tolerate the Chinese medicine. Three
cases from the treatment group were lost to follow-up.
From the control group, 2 cases were lost to follow-up,
2 patients showed diminished interest in participation,
3 patients experienced nausea, and 2 patients had ab-
dominal distension. As a result, 168 patients complet-
ed the study, with 86 cases in the treatment group and
82 cases in the control group.
Baseline comparison
Among the two groups there were no significant differ-
ences in sex, age and education. Therefore, the two
groups were comparable and had a balanced baseline
(P > 0.05, Table 1).
Comparison of efficacy index
For both groups in this study, the post-treatment levels
of FPG, FIns, HbA1c, HOMA-IR, MMSE, MoCA,
ET-1 and NO were better than pre-treatment, The dif-
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ferences were statistically significant (P < 0.05, Table
2). The post-treatment levels in the treatment group
for FPG, FIns, HbA1c, HOMA-IR, MMSE, MoCA,
ET-1 and NO were better than for the control group.
The differences were statistically significant (P < 0.05,
Table 2).
Evaluation of safety
More adverse reactions occurred in the control group
than in the treatment group. In the treatment group, 3
patients suffered from mild nausea and 5 patients vom-
ited. In the control group, 7 patients suffered from
mild nausea, 9 patients vomited, 5 experienced moder-
ate diarrhea, and 11 patients had abdominal disten-
sion. There was a significant difference in the number
of adverse reactions between the two groups (P < 0.05).
DISCUSSION
As can be experienced with the aging progress, the inci-
dence of type 2 DM and VaD is increasing. There has
been an increasing body of evidence linking IR to cog-
nitive decline and dementia in patients with diabe-
tes.13,14 Epidemiologic studies of elder adults have
found that type 2 DM is associated with an increased
risk of subsequent development of dementia.15,16 There-
fore, diabetic control from an early stage of IR would
be useful to prevent VaD. In this study, we observed
the effect of Sancaijiangtang powders on the levels of
NO and ET-1, and aimed to describe the potential
treatment of two different diseases, type 2 DM and
VaD, using the same method of TCM.
This 12-week study has shown that the post-treatment
levels of FPG, FIns, HbA1c, HOMA-IR, MMSE, Mo-
CA, ET-1 and NO in both treatment and control
groups were better than those measured pre-treatment
(P < 0.05). The post-treatment levels of FPG, FIns,
HbA1c, HOMA-IR, MMSE, MoCA, ET-1 and NO
in the treatment group were better than those mea-
sured for the control group (P < 0.05).
The Sancaijiangtang powders, a variation of a classical
traditional Chinese prescription, were first mentioned
in the book Wen Bing Tiao Bian17 in the Qing Dynasty.
The powders consist of Renshen (Radix Ginseng), Tian-
dong (Radix Asparagi Cochinchinensis), Dihuang (Radix
Rehmanniae), Wumei (Fructus Mume), Rougui (Cortex
Cinnamomi Cassiae), Huanglian (Rhizoma Coptidis)
and others. The main treatment effect described was a
clearing of heat, moistening dryness, and a balancing
of Yin and Yang.
Modern pharmacological research has found that gin-
senosides Rb1, Rg1, Rg3, Rh2, Re, and IH-901 exert
anti-diabetic, and anti-oxidant effects.18-21 Data from
studies conducted in animal models has identified that
the ginsenoside Re can affect insulin sensitivity in
3T3-L1 adipocytes,22 and improve glycemic control.23
Other ginsenoside species (Re, Rb1) have shown im-
proved insulin-stimulated glucose disposal.18,24 Dihuang
(Radix Rehmanniae) has been shown to have an inhibit-
ing effect on advanced glycosylation end products (AG-
Es), which react on ED. The mechanism might be re-
lated to that for the inhibition of endothelial cell oxida-
Table 1 Comparison of basic clinical characteristics between the two groups ( xˉ ± s)
Group
TCM+WM
WM
n (M/F)
86 (45/41)
82 (43/39)
Mean age (years)
59.1±11.4
61.0±11.3
BMI (kg/m2)
24.7±4.1
25.2±3.9
Mean disease
course (years)
14.9±1.8
15.3±2.0
Degree of education (illiterate/primary school/
middle school/college degree or above) (n)
4/27/48/7
3/25/49/5
Notes: TCM+WM: the treatment group; WM: the control group. Patients in the treatment group were treated with Sancaijiangtang
powders and with pioglitazone hydrochloride. Patients in the control group were treated with pioglitazone hydrochloride alone. M: male;
F: female; BMI: body mass index.
Table 2 Comparison of the efficacy index between the two test groups before and after treatment ( xˉ ± s)
Notes: TCM+WM: the treatment group; WM: the control group. Patients in the treatment group were treated with Sancaijiangtang
powders and with pioglitazone hydrochloride. Patients in the control group were treated with pioglitazone hydrochloride alone. FPG:
fasting plasma glucose; FIns: fasting insulin; HbA1c: hemoglobin A1c; MMSE: mini-mental state examination; MoCA: montreal cognitive
assessment; HOMA-IR: homeostasis model assessment-insulin resistance; ET-1: endothelin-1; NO: nitric oxide. Statistical significance
between figures compared with WM group is aP < 0.05. Statistical significance between figures compared with those pre-treatment figures
in the same group is bP < 0.05.
Group
TCM+WM
WM
Group
TCM+WM
WM
n
86
82
n
86
82
FPG (mmol/L)
Pre-
9.4±1.1
9.4±1.3
MoCA (scores)
Pre-
13.9±3.7
12.9±3.6
Post-
7.5±1.0ab
7.8±1.2b
Post-
15.8±2.8ab
14.6±3.4b
FIns (mU/L)
Pre-
14.4±0.7
14.0±2.2
HOMA-IR
Pre-
6.0±0.8
5.8±1.2
Pre-
13.8±3.3ab
9.9±1.9b
Post-
4.6±1.3ab
3.5±0.8b
HbA1c (%)
Post-
8.4±1.0
8.2±1.2
NO (μmol/L)
Pre-
32.3±6.4
33.4±5.9
Post-
7.3±0.9ab
7.7±1.0b
Post-
43.0±6.0ab
41.0±5.3b
MMSE (scores)
Pre-
15.0±4.8
15.1±3.8
ET-1 (ng/L)
Pre-
94.5±12.4
92.0±13.3
Post-
19.1±3.5ab
17.1±3.8b
Post-
76.0±7.3ab
80.9±6.9b
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tive stress, reduction of the generation of inflammation
factors, and regulation of the secretion from endotheli-
al cells. Several studies have reported that constituents
of Tiandong (Radix Asparagi Cochinchinensis) root ex-
tracts can enhance insulin secretion from a perfused
pancreas, isolated islets and clonal pancreatic be-
ta-cells.25 The constituents had wide-ranging stimulato-
ry effects on physiological insulinotropic pathways,
which could reduce blood glucose in rats and rabbits.
Huanglian (Rhizoma Coptidis) mainly consists of ber-
berine, which can increase the action of glucose trans-
porter type 4 and glucose uptake, decrease peroxisome
proliferator-activated receptor (PPAR) δ mRNA levels,
and reduce IR in insulin-resistant theca-cells.26 Some
studies have addressed the important role of PPAR-γ
in the regulation of insulin sensitivity and glucose ho-
meostasis.27 Huanglian (Rhizoma Coptidis) extracts im-
proved tumor necrosis factor-α-reduced expression of
PPAR-γ mRNA, which indicates that it might im-
prove IR. Rougui (Cortex Cinnamomi Cassiae) largely
contains cinnamaldehyde and cinnamic acid, which
has also been demonstrated to exhibit beneficial effects
in attenuating disturbances of glucose and lipid metab-
olism.28,29 Animal experiments have shown that Wumei
(Fructus Mume) can lower blood sugar, reduce AGEs,
and improve the metabolic disorder and IR in a type 2
diabetic model of rats.
ED, characterized by reduced bioavailability of NO
and increased activity of the vasoconstrictor and proin-
flammatory peptide ET-1, has been present in insu-
lin-resistant states,30 and has occurred in both animal
models of diabetes, diabetic patients and patients with
VaD. NO is released from the endothelium of blood
vessels and causes vasodilation via cyclic guanosine mo-
nophosphate (cGMP).31 Excessive reactive oxygen spe-
cies are possibly produced by the NO. Generation of
the toxic oxidant peroxynitrite results in ED in diabe-
tes. An increased production of superoxide in endothe-
lial cells causes a direct reaction with NO to form the
more harmful molecule peroxynitrite (ONOOˉ),
which reduces NO bioavailability.32 Disturbances in
NO bioavailability have been found to cause ED, and
lead to increased susceptibility to DM,33 vasodilatation
and increased blood flow, which in turn stimulates glu-
cose uptake in skeletal muscle.34 ET-1, a potent vaso-
constrictor chronically elevated in type 2 DM, stimu-
lates the production of reactive oxygen species. An ex-
perimental model in non-obese moderately diabetic
rats showed that the ET-1 system contributes to in-
creased oxidative stress.35 The system had an impaired
insulin-stimulated GLUT4 translocation in adipo-
cytes,36,37 and decreased PI3-kinase activity via insulin
receptor substrate-2 Ser and Tyr phosphorylation in iso-
lated vascular smooth muscle cells.38 Furthermore,
ET-1 could reduce peripheral glucose utilization,39 and
insulin sensitivity.40 Therefore, plasma ET-1 levels are
elevated and NO levels are lower in type 2 DM.
In conclusion, the two treatment groups displayed a
certain curative effect on the condition of type 2 DM
and VaD. Sancaijiangtang powders combined with pio-
glitazone hydrochloride can effectively improve levels
of FPG, FIns, HbA1c, HOMA-IR, MMSE and Mo-
CA. The effects of these drug combinations in decreas-
ing plasma ET-1 and increasing NO levels are more evi-
dent than have been described in Western medicine.
The drug combinations show significant advantages in
IR, hyperinsulinemia and ED. Moreover, the drug
combinations have a reduced occurrence of adverse re-
actions.
This study confirmed that IR and ED can be improved
by treatment with Sancaijiangtang powders and
through multiple mechanisms. These include promot-
ing insulin secretion, increasing insulin sensitivity, de-
creasing plasma ET-1 levels, increasing NO levels to
improve microcirculation, preventing vasoconstriction,
maintaining vessel elasticity, assuring enough blood
flow, and improving the metabolism of the nerve cells
and restoring function thereby preventing degenera-
tion of neurons. Therefore, treatment can significantly
improve VaD symptoms. Sancaijiangtang powders can
effectively improve ED, IR, hyperinsulinemia, and the
symptoms of mild VaD.
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